Coherus BioSciences (CHRS) – Management Comments
-
Coherus BioSciences (CHRS) sees 2026 net sales of $1.2 billion to $2.2 billion
-
Coherus BioSciences (CHRS) BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CHRS Stock Lookup